Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer
Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.
Related Articles
AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning
Krishnansu S. Tewari, MD, and Kimberly Futch, MBA, detail considerations with AI programs, and roles AI may have in early diagnosis, time reduction in the…
First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC
The CHMP has recommended the European approval of serplulimab for the first-line treatment of extensive-stage small cell lung cancer.
BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC
BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.
NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC
An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.
CINtec PLUS Receives WHO Endorsement in Cervical Cancer Prevention Guidelines
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC
Isabel Preeshagul, DO, MBS, discusses ongoing efforts to expand treatment options for patients with extensive- or limited-stage small cell lung cancer.
Park and Grivas Expand on Treatment Updates in Bladder Cancer
Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.
Gotistobart Plus Pembrolizumab Shows Activity in Platinum-Resistant Ovarian Cancer
Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.
Unmet Needs and Future Direction in HER2+ Breast Cancer
The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.